Uterine fibroids (UFs) are benign smooth muscle neoplasms affecting up to 70% of reproductive age women. Treatment of symptomatic UFs places a significant economic burden on the US health-care system. Several specific genetic abnormalities have been described as etiologic factors of UFs, suggesting that a low DNA damage repair capacity may be involved in the formation of UF. In this study, we used human fibroid and adjacent myometrial tissues, as well as an in vitro cell culture model, to evaluate the expression of MutS homolog 2 (MSH2), which encodes a protein belongs to the mismatch repair system. In addition, we deciphered the mechanism by which polycomb repressive complex 2 protein, EZH2, deregulates MSH2 in UFs. The RNA expression analysis demonstrated the deregulation of MSH2 expression in UF tissues in comparison to its adjacent myometrium. Notably, protein levels of MSH2 were upregulated in 90% of fibroid tissues (9 of 10) as compared to matched adjacent myometrial tissues. Human fibroid primary cells treated with 3-deazaneplanocin A (DZNep), chemical inhibitor of EZH2, exhibited a significant increase in MSH2 expression (P < .05). Overexpression of EZH2 using an adenoviral vector approach significantly downregulated the expression of MSH2 (P < .05). Chromatin immunoprecipitation assay demonstrated that enrichment of H3K27me3 in promoter regions of MSH2 was significantly decreased in DZNep-treated fibroid cells as compared to vehicle control. These data suggest that EZH2-H3K27me3 regulatory mechanism dynamically changes the expression levels of DNA mismatch repair gene MSH2, through epigenetic mark H3K27me3. MSH2 may be considered as a marker for early detection of UFs.
BulunSE. Uterine fibroids. N Engl J Med. 2013;369(14):1344–1355.
2.
Al-HendyASalamaS. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006;12(4):385–400.
3.
HeinonenHRSarvilinnaNSSjobergJ. MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertil Steril. 2014;102(4):1137–1142.
4.
RiekerRJAgaimyAMoskalevEA. Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis peritonealis disseminata). Pathology. 2013;45(4):388–392.
5.
HalderSKLaknaurAMillerJLaymanLCDiamondMAl-HendyA. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015;290(2):505–511.
6.
BertschEQiangWZhangQ. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014;27(8):1144–1153.
7.
HunterDSKlotzbucherMKugohH. Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function. Cancer Res. 2002;62(13):3766–3772.
8.
IngrahamSELynchRASurtiU. Identification and characterization of novel human transcripts embedded within HMGA2 in t(12;14)(q15;q24.1) uterine leiomyoma. Mutat Res. 2006;602(1-2):43–53.
9.
El-ShennawyGAElbialyAAIsamilAEEl BeheryMM. Is genetic polymorphism of ER-alpha, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma?Arch Gynecol Obstet. 2011;283(6):1313–1318.
10.
VikhliaevaEM.Molecular-genetic determinants of the neoplastic process and state-of-the-art treatment of patients with uterine leiomyoma [in Russian]. Vopr Onkol. 2001;47(2):200–204.
11.
YangYZhaiXDGaoLBLiSLWangZChenGD. Genetic polymorphisms of DNA repair gene XRCC1 and risk of uterine leiomyoma. Mol Cell Biochem. 2010;338(1-2):143–147.
12.
RamosJMRuizAColenRLopezIDGrossmanLMattaJL. DNA repair and breast carcinoma susceptibility in women. Cancer. 2004;100(7):1352–1357.
13.
Ricks-SantiLJSuchestonLEYangY. Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. BMC Cancer. 2011;11:278.
14.
HelledayTPetermannELundinCHodgsonBSharmaRA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
15.
BenhamouSSarasinA. Variability in nucleotide excision repair and cancer risk: a review. Mutat Res. 2000;462(2-3):149–158.
16.
MattaJLVillaJLRamosJM. DNA repair and nonmelanoma skin cancer in Puerto Rican populations. J Am Acad Dermatol. 2003;49(3):433–439.
17.
BelchevaAKolajBMartinA. Missing mismatch repair: a key to T cell immortality. Leuk Lymphoma. 2010;51(10):1777–1778.
BachmannIMHalvorsenOJCollettK. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–273.
20.
KleerCGCaoQVaramballyS. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11611.
21.
LeeWTeckieSWiesnerT. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227–1232.
StefanssonOAEstellerM. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells. Breast Cancer Res. 2011;13(3):309.
24.
YooKHHennighausenL. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 2012;8(1):59–65.
25.
YuHSimonsDLSegallI. PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PloS One. 2012;7(12):e51239.
26.
YamaguchiHHungMC. Regulation and role of EZH2 in cancer. Cancer Res Treat. 2014;46(3):209–222.
27.
ChangCJHungMC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106(2):243–247.
28.
ChenYHHungMCLiLY. EZH2: a pivotal regulator in controlling cell differentiation. Am J Transl Res. 2012;4(4):364–375.
29.
HolmKGrabauDLovgrenK. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012;6(5):494–506.
30.
TanJZYanYWangXXJiangYXuHE. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin. 2014;35(2):161–174.
31.
KondoY. Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem. 2014;156(5):249–257.
32.
ChangCJYangJYXiaW. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011;19(1):86–100.
33.
PuppeJDrostRLiuX. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009;11(4):R63.
34.
ZeidlerMVaramballySCaoQ. The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia. 2005;7(11):1011–1019.
35.
AkinyemiBOAdewoyeBRFakoyaTA. Uterine fibroid: a review. Niger J Med. 2004;13(4):318–329.
36.
YangQMasADiamondMPAl-HendyA. The mechanism and function of epigenetics in uterine leiomyoma development. Reprod Sci. 2016;23(2):163–175.
37.
CarneySATaharaHSwartzCD. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest. 2002;82(6):719–728.
38.
HalderSKOsteenKGAl-HendyA. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28(9):2407–2416.
39.
NairSCurielDTRajaratnamVThotaCAl-HendyA. Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Hum Reprod. 2013;28(9):2398–2406.
40.
NairSSaedGMAttaHM. Towards gene therapy of postoperative adhesions: fiber and transcriptional modifications enhance adenovirus targeting towards human adhesion cells. Gynecol Obstet Invest. 2013;76(2):119–124.
41.
YangQSunMRamchandranRRajJU. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: role of epigenetic regulation. Vascular Pharmacol. 2015;73:20–31.
42.
YangQTianYOstlerKR. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer. 2010;10:286.
43.
YangQDahlMJAlbertineKHRamchandranRSunMRajJU. Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells. Cell Prolif. 2013;46(6):654–664.
44.
IwahashiYItoEYanagisawaY. Promoter analysis of the human mismatch repair gene hMSH2. Gene. 1998;213(1-2):141–147.
45.
YamamotoHImaiK. Microsatellite instability: an update. Arch Toxicol. 2015;89(6):899–921.
46.
CampbellMRWangYAndrewSELiuY. MsH2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect. Oncogene. 2006;25(17):2531–2536.
47.
CampbellMRNationPNAndrewSE. A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy. Cancer Res. 2005;65(7):2626–2635.
48.
WheelerVCLebelLAVrbanacVTeedAte RieleHMacDonaldME. Mismatch repair gene MsH2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet. 2003;12(3):273–281.
49.
LalGAshCHayK. Suppression of intestinal polyps in MsH2-deficient and non-MsH2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 2001;61(16):6131–6136.
50.
BridgeGRashidSMartinSA. DNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment. Cancers. 2014;6(3):1597–1614.
51.
RussoMTDe LucaGCasorelliI. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis. Cancer Res. 2009;69(10):4372–4379.
52.
MeiraLBCheoDLReisAM. Mice defective in the mismatch repair gene MsH2 show increased predisposition to UVB radiation-induced skin cancer. DNA Repair. 2002;1(11):929–934.
53.
ReitmairAHSchmitsREwelA. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet. 1995;11(1):64–70.
54.
YooKHWonKYLimSJParkYKChangSG. Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma. Oncol Lett. 2014;8(5):2135–2139.
55.
PritchardCCMorrisseyCKumarA. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 2014;5:4988.
56.
HaraldsdottirSHampelHTomsicJ. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147(6):1308–1316.e1301.
57.
AmantFDorflingCMDreyerLVergoteILindequeBGVan RensburgEJ. Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer. 2001;11(3):218–223.
58.
HoangLNAliRHLauSGilksCBLeeCH. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. Int J Gynecol Pathol. 2014;33(5):483–491.
59.
VaramballySDhanasekaranSMZhouM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–629.
60.
VisserHPGunsterMJKluin-NelemansHC. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001;112(4):950–958.
61.
CaoWYounisRHLiJ. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res (Phila). 2011;4(11):1816–1824.
62.
ChaseACrossNC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9):2613–2618.
63.
SimonJALangeCA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647(1-2):21–29.
64.
WuZLeeSTQiaoY. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 2011;18(11):1771–1779.
65.
SauvageauMSauvageauG. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3):299–313.
66.
NakagawaSSakamotoYOkabeH. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncol Rep. 2014;31(2):983–988.
67.
KikuchiJTakashinaTKinoshitaI. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012;78(2):138–143.
68.
CreaFHurtEMMathewsLA. Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011;10:40.
69.
KondoYShenLChengAS. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741–750.
70.
BrackenAPKleine-KohlbrecherDDietrichN. The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007;21(5):525–530.
71.
FanTJiangSChungN. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 2011;9(4):418–429.
72.
ZhongJMinLHuangH. EZH2 regulates the expression of p16 in the nasopharyngeal cancer cells. Technol Cancer Res Treat. 2013;12(3):269–274.
73.
LinLZhengYTuY. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. Hum Pathol. 2015;46(7):971–980.
74.
ChenDLZhangDSLuYX. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget. 2015;6(13):10868–10879.
75.
LiuFHeYShuRWangS. MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2. Int J Clin Exp Pathol. 2015;8(5):4972–4980.
76.
SunJZhengGGuZGuoZ. MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2. J Neurooncol. 2015;122(3):481–489.
77.
CanevariRAPontesARosaFERainhoCARogattoSR. Independent clonal origin of multiple uterine leiomyomas that was determined by X chromosome inactivation and microsatellite analysis. Am J Obstet Gynecol. 2005;193(4):1395–1403.
78.
FrenchDCermeleCLombardiAM. Microsatellite alterations in uterine leiomyomas. Anticancer Res. 1998;18(1A):349–351.
79.
LiMLiuLWangZ. Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep. 2008;19(2):401–406.
80.
DraceaAAngelescuCDanciulescuMCiureaMIoanaMBuradaF. Mismatch repair gene expression in gastroesophageal cancers. Turk J Gastroenterol. 2015;26(5):373–377.
81.
ZhangMXiangSJooHY. HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα. Molecular Cell. 2014;55(1):31–46.
82.
TanJYangXZhuangL. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21(9):1050–1063.
83.
MullerJVerrijzerP. Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr Opin Genet Dev. 2009;19(2):150–158.
84.
VolkelPDupretBLe BourhisXAngrandPO. Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res. 2015;7(2):175–193.
85.
ShiBLiangJYangX. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007;27(14):5105–5119.
86.
LeeSTLiZWuZ. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Molecular Cell. 2011;43(5):798–810.
87.
GaoSBZhengQFXuB. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma. Mol Cancer Res. 2014;12(10):1388–1397.
88.
ZeidlerMKleerCG. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol. 2006;37(5-7):219–223.
